Arvid. W. A. Kamps
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arvid. W. A. Kamps has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Lidy van Lente
Martini Academy, Martini Hospital
11 shared publications- Wouter W. de Weger
Department of Paediatrics Martini Hospital Groningen The Netherlands
8 shared publications Gerbrich N. van der Meulen
Department of Paediatrics Martini Hospital Groningen The Netherlands
7 shared publications- Gerard H. Koppelman
Department of Pediatric Pulmonology and Pediatric Allergology University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital Groningen The Netherlands
6 shared publications - Aline. B. Sprikkelman
Department of Pediatrics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands
5 shared publications Annemie L. M. Boehmer
Spaarne Gasthuis
5 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0361579
Nurse-Led treatment strategy based on asthma score and oxygen requirement in children with acute reversible bronchoconstriction: A randomised controlled non-inferiority trial
Objective: The Childhood Asthma Score (CAS) does not fully account for oxygen therapy in children with acute reversible bronchoconstriction (ARB), thus the CAS O2 was developed. Our aim was to assess effectiveness and safety of the CAS O2 treatment protocol compared to the CAS protocol. Design: Multicentre, open-label, randomised, non-inferiority trial. Setting: Two Dutch teaching hospitals with general paediatric wards. Patients: Children 2–18 years admitted with ARB, requiring supplemental oxygen. Interventions: Nurse led treatment strategies using CAS O 2 (tailored for patients receiving supplemental oxygen) or CAS to guide bronchodilator administration and reassessment intervals. Main outcome measure: Length of hospital stay (LOS); non-inferiority margin of 8 hours. Results: Data of 132 children who required supplemental oxygen were analysed (CAS O2 group n = 69; CAS n = 63). Median LOS was 40.0 hours (IQR 25.5–47.0) with CAS O 2 and 40.8 hours (IQR 27.1–65.2) with CAS. The adjusted absolute difference in LOS (CAS O 2 − CAS) was −3.7 hours (95% CI −10.2 to 4.1), meeting non inferiority. Bronchodilator administrations were fewer with CAS O2 (mean 7.9 versus 10.5; rate ratio 0.75, (95% CI 0.64–0.88; p < 0.001). Safety outcomes (physician assessments, intravenous magnesium sulphate or salbutamol, PICU transfer, 7 day readmission) did not differ between groups. Conclusions: Compared with CAS, CAS O 2 supports nurse-led management of children hospitalised with ARB, including those requiring supplemental oxygen, with fewer bronchodilator administrations and no prolongation of LOS. These findings support broader implementation of CAS O2 -based pathways.
- 30 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0361579
Open AccessNurse-Led treatment strategy based on asthma score and oxygen requirement in children with acute reversible bronchoconstriction: A randomised controlled non-inferiority trial
Objective: The Childhood Asthma Score (CAS) does not fully account for oxygen therapy in children with acute reversible bronchoconstriction (ARB), thus the CAS O2 was developed. Our aim was to assess effectiveness and safety of the CAS O2 treatment protocol compared to the CAS protocol. Design: Multicentre, open-label, randomised, non-inferiority trial. Setting: Two Dutch teaching hospitals with general paediatric wards. Patients: Children 2–18 years admitted with ARB, requiring supplemental oxygen. Interventions: Nurse led treatment strategies using CAS O 2 (tailored for patients receiving supplemental oxygen) or CAS to guide bronchodilator administration and reassessment intervals. Main outcome measure: Length of hospital stay (LOS); non-inferiority margin of 8 hours. Results: Data of 132 children who required supplemental oxygen were analysed (CAS O2 group n = 69; CAS n = 63). Median LOS was 40.0 hours (IQR 25.5–47.0) with CAS O 2 and 40.8 hours (IQR 27.1–65.2) with CAS. The adjusted absolute difference in LOS (CAS O 2 − CAS) was −3.7 hours (95% CI −10.2 to 4.1), meeting non inferiority. Bronchodilator administrations were fewer with CAS O2 (mean 7.9 versus 10.5; rate ratio 0.75, (95% CI 0.64–0.88; p < 0.001). Safety outcomes (physician assessments, intravenous magnesium sulphate or salbutamol, PICU transfer, 7 day readmission) did not differ between groups. Conclusions: Compared with CAS, CAS O 2 supports nurse-led management of children hospitalised with ARB, including those requiring supplemental oxygen, with fewer bronchodilator administrations and no prolongation of LOS. These findings support broader implementation of CAS O2 -based pathways.
- 21 April 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (4) , e70352
Spontaneous resolution of peanut and tree nut allergies: Rationale for repeating challenges
- 21 April 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (4) , e70352
Spontaneous resolution of peanut and tree nut allergies: Rationale for repeating challenges
- 9 June 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (9) , 2391-2393
Diagnosing Dysfunctional Breathing Using the Nijmegen Questionnaire or Visual Assessment of Breathing Pattern
- 9 June 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (9) , 2391-2393
Diagnosing Dysfunctional Breathing Using the Nijmegen Questionnaire or Visual Assessment of Breathing Pattern
- Open Access
Safe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: protocol for a randomised controlled trial (OxyKids study)
Introduction Little is known about the effectiveness and safety of oxygen saturation (SpO2) thresholds in children admitted with respiratory distress. The current 90%–94% threshold could lead to prolonged administration of supplemental oxygen, increased duration of hospital admissions, distress for children and families, and healthcare costs. To balance reducing unnecessary oxygen administration and preventing hypoxia, a lower SpO2 threshold of 88% for oxygen supplementation in children has been suggested. This trial aims to test the hypothesis that a lower SpO2 threshold of 88% safely reduces the length of hospital stay in children admitted with respiratory distress when compared with a 92% SpO2 threshold and to assess its cost-effectiveness. Methods and analysis This is a multicentre, open-label, randomised controlled trial with two parallel arms. A total of 560 children aged 6 weeks to 12 years admitted with a diagnosis of bronchiolitis, viral wheeze or lower respiratory tract infection will be recruited and equally randomised into an intervention or usual care arm. Intervention arm patients will receive supplemental oxygen if SpO2 falls below 88% or above 88% if deemed necessary by clinical staff. Control arm patients will receive supplemental oxygen if SpO2 falls below 92% or above 92% if deemed necessary by staff. The primary outcome is the time from admission to the time when all prespecified discharge criteria are met. Secondary outcomes are length of stay, safety (time to recovery, readmissions and paediatric intensive care admissions), quality of life, parental anxiety and societal costs. Patients are followed up by digital questionnaires up to 90 days postdischarge. Ethics and dissemination This study has received approval from the research ethics committee (REC) of Leiden, Den Haag and Delft (EU CT number 2023-504817-56). Written informed consent will be obtained from parents or guardians. Parents of patients and patient representatives are involved in all stages of the study, from design to results, interpretation and dissemination. The results of this trial will be disseminated via lay publications, peer-reviewed scientific journals and academic conferences. Trial registration number NCT06016244.
Open AccessSafe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: protocol for a randomised controlled trial (OxyKids study)
Introduction Little is known about the effectiveness and safety of oxygen saturation (SpO2) thresholds in children admitted with respiratory distress. The current 90%–94% threshold could lead to prolonged administration of supplemental oxygen, increased duration of hospital admissions, distress for children and families, and healthcare costs. To balance reducing unnecessary oxygen administration and preventing hypoxia, a lower SpO2 threshold of 88% for oxygen supplementation in children has been suggested. This trial aims to test the hypothesis that a lower SpO2 threshold of 88% safely reduces the length of hospital stay in children admitted with respiratory distress when compared with a 92% SpO2 threshold and to assess its cost-effectiveness. Methods and analysis This is a multicentre, open-label, randomised controlled trial with two parallel arms. A total of 560 children aged 6 weeks to 12 years admitted with a diagnosis of bronchiolitis, viral wheeze or lower respiratory tract infection will be recruited and equally randomised into an intervention or usual care arm. Intervention arm patients will receive supplemental oxygen if SpO2 falls below 88% or above 88% if deemed necessary by clinical staff. Control arm patients will receive supplemental oxygen if SpO2 falls below 92% or above 92% if deemed necessary by staff. The primary outcome is the time from admission to the time when all prespecified discharge criteria are met. Secondary outcomes are length of stay, safety (time to recovery, readmissions and paediatric intensive care admissions), quality of life, parental anxiety and societal costs. Patients are followed up by digital questionnaires up to 90 days postdischarge. Ethics and dissemination This study has received approval from the research ethics committee (REC) of Leiden, Den Haag and Delft (EU CT number 2023-504817-56). Written informed consent will be obtained from parents or guardians. Parents of patients and patient representatives are involved in all stages of the study, from design to results, interpretation and dissemination. The results of this trial will be disseminated via lay publications, peer-reviewed scientific journals and academic conferences. Trial registration number NCT06016244.
- Open Access
Comparison of Double‐Blind and Open Food Challenges for the Diagnosis of Food Allergy in Childhood: The ALDORADO Study
Background: Double‐blind placebo‐controlled food challenge (DBPCFC) is widely regarded as the “gold standard” to diagnose food allergy. Maximum efforts are made to reduce bias, yet DBPCFCs are costly, time‐, and resource‐intensive. Less demanding open food challenges are increasingly used in clinical practice. However, recommendations regarding the use of these challenges are based on low certainty of evidence, and no comparative studies have been performed using the most recent international food challenge guidelines. We hypothesised that the open food challenge is non‐inferior to DBPCFC in children suspected of allergy to cashew nuts, hazelnuts or peanuts.Methods: A total of 63 children, aged 4 years and older, were included if referred for suspected IgE‐mediated allergy to cashew nut, hazelnut, or peanut. All study participants underwent DBPCFC first, followed by an open food challenge for the same food. Challenge outcomes were assessed by predefined criteria into positive, negative, or inconclusive.Results: DBPCFC and open food challenge outcomes were the same for 36/41 (87.8%) patients. Sensitivity and specificity of the open food challenge were 0.91 (95% CI 0.79, 1.03) and 0.83 (95% CI 0.63, 1.01), respectively, with an AUC value of 0.87. Eliciting and stop doses were not significantly different between both food challenges.Conclusion: The Diagnostic accuracy of open food challenge is non‐inferior to that of DBPCFC. This finding implies less demanding open food challenges can be implemented for children from the age of 4 years suspected to be cashew nut, hazelnut, or peanut allergic. Further research is necessary to validate our findings and to investigate the diagnostic accuracy for other major food allergens.
Open AccessComparison of Double‐Blind and Open Food Challenges for the Diagnosis of Food Allergy in Childhood: The ALDORADO Study
Background: Double‐blind placebo‐controlled food challenge (DBPCFC) is widely regarded as the “gold standard” to diagnose food allergy. Maximum efforts are made to reduce bias, yet DBPCFCs are costly, time‐, and resource‐intensive. Less demanding open food challenges are increasingly used in clinical practice. However, recommendations regarding the use of these challenges are based on low certainty of evidence, and no comparative studies have been performed using the most recent international food challenge guidelines. We hypothesised that the open food challenge is non‐inferior to DBPCFC in children suspected of allergy to cashew nuts, hazelnuts or peanuts.Methods: A total of 63 children, aged 4 years and older, were included if referred for suspected IgE‐mediated allergy to cashew nut, hazelnut, or peanut. All study participants underwent DBPCFC first, followed by an open food challenge for the same food. Challenge outcomes were assessed by predefined criteria into positive, negative, or inconclusive.Results: DBPCFC and open food challenge outcomes were the same for 36/41 (87.8%) patients. Sensitivity and specificity of the open food challenge were 0.91 (95% CI 0.79, 1.03) and 0.83 (95% CI 0.63, 1.01), respectively, with an AUC value of 0.87. Eliciting and stop doses were not significantly different between both food challenges.Conclusion: The Diagnostic accuracy of open food challenge is non‐inferior to that of DBPCFC. This finding implies less demanding open food challenges can be implemented for children from the age of 4 years suspected to be cashew nut, hazelnut, or peanut allergic. Further research is necessary to validate our findings and to investigate the diagnostic accuracy for other major food allergens.
- 2 February 2024
- Published by Taylor & Francis in Journal of Asthma
- Vol. 61 (8) , 876-882
Assessment of acute asthma in children: do parents and healthcare providers speak the same language?
ObjectiveEducation and self-management plans enhance parents' self-efficacy in managing their child's asthma symptoms. By understanding how parents recognize and interpret acute asthma symptoms, we can compile patient information using terms that are familiar to parents.MethodSemi-structured interviews were carried out with 27 parents of children with asthma aged 2-12 years. The interviewees were selected from three groups: parents of children admitted for acute asthma, parents of children receiving outpatient asthma care, and parents who had access to a self-management plan. Parents were invited to report symptoms they would associate with acute asthma. Subsequently, parents were queried about their recognition of symptoms from a predefined list and asked to explain how they would assess these symptoms in case their child would experience an attack of acute asthma.ResultsThe most frequently reported symptoms for acute asthma were shortness of breath (77.8%) and coughing (63%). Other signs such as retractions, nasal flaring, and wheezing were reported by less than 25% of the parents. All parents recognized shortness of breath, wheezing and gasping for breath from a predefined list of medical terms. Retractions and nasal flaring were recognized by 81.5% and 66.7% of the parents, respectively. Recognizing the medical terms did not necessarily translate into parents being able to explain how to assess these symptoms.ConclusionParents and healthcare professionals do not always speak the same language concerning symptoms of acute asthma. This may hamper timely recognition and adequate self-management, highlighting the necessity to adjust current medical information about acute asthma.
- 2 February 2024
- Published by Taylor & Francis in Journal of Asthma
- Vol. 61 (8) , 876-882
Assessment of acute asthma in children: do parents and healthcare providers speak the same language?
ObjectiveEducation and self-management plans enhance parents' self-efficacy in managing their child's asthma symptoms. By understanding how parents recognize and interpret acute asthma symptoms, we can compile patient information using terms that are familiar to parents.MethodSemi-structured interviews were carried out with 27 parents of children with asthma aged 2-12 years. The interviewees were selected from three groups: parents of children admitted for acute asthma, parents of children receiving outpatient asthma care, and parents who had access to a self-management plan. Parents were invited to report symptoms they would associate with acute asthma. Subsequently, parents were queried about their recognition of symptoms from a predefined list and asked to explain how they would assess these symptoms in case their child would experience an attack of acute asthma.ResultsThe most frequently reported symptoms for acute asthma were shortness of breath (77.8%) and coughing (63%). Other signs such as retractions, nasal flaring, and wheezing were reported by less than 25% of the parents. All parents recognized shortness of breath, wheezing and gasping for breath from a predefined list of medical terms. Retractions and nasal flaring were recognized by 81.5% and 66.7% of the parents, respectively. Recognizing the medical terms did not necessarily translate into parents being able to explain how to assess these symptoms.ConclusionParents and healthcare professionals do not always speak the same language concerning symptoms of acute asthma. This may hamper timely recognition and adequate self-management, highlighting the necessity to adjust current medical information about acute asthma.
- Open Access
- 19 January 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (1) , e1152
Eliciting and stop dose during oral food challenges for peanut and common tree nuts in different age groups
Background: Oral food challenges (OFCs) are used to confirm or reject a diagnosis of food allergy. However, younger children may encounter difficulties in consuming all offered doses during an OFC in the absence of symptoms, resulting in inconclusive outcomes. Our aim is to assess the eliciting dose for objective symptoms among various age groups and determine the necessity of consuming the final dose step during an uneventful OFC to avoid false negative outcomes.Methods: OFCs for common food allergens performed between 2012 and 2019 were analyzed retrospectively. The primary outcome was the association of age with stop dose for OFCs with inconclusive outcome. Secondary outcome measures were the association of age with eliciting dose and the potential number of false negative outcomes.Results: A total of 1327 OFCs were performed in 707 patients. Of these, 514 (38.7%) were positive, 589 (44.4%) negative, and 224 (16.9%) inconclusive. In OFCs with inconclusive outcome, age appeared to be a significant predictor of the stop dose only for almond (p = .005). Objective symptoms occurred after the last dose step in 2%–13% of all OFCs with positive outcome. In our cohort, potential false negative outcomes may have been drawn in 27.6% of uneventful OFCs.Conclusions: Two third of children under 6 years of age successfully consumed all the provided doses during OFCs with a negative outcome. The eliciting dose for objective symptoms was not associated with age, and in a substantial number of OFCs with positive outcome, symptoms occurred after eating the final dose. These findings suggest that in case of an uneventful OFC, the outcome should be drawn only after a cumulative dose of 4.4 g has been consumed to avoid the risk of a potential false negative outcome.
- 19 January 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (1) , e1152
Open AccessEliciting and stop dose during oral food challenges for peanut and common tree nuts in different age groups
Background: Oral food challenges (OFCs) are used to confirm or reject a diagnosis of food allergy. However, younger children may encounter difficulties in consuming all offered doses during an OFC in the absence of symptoms, resulting in inconclusive outcomes. Our aim is to assess the eliciting dose for objective symptoms among various age groups and determine the necessity of consuming the final dose step during an uneventful OFC to avoid false negative outcomes.Methods: OFCs for common food allergens performed between 2012 and 2019 were analyzed retrospectively. The primary outcome was the association of age with stop dose for OFCs with inconclusive outcome. Secondary outcome measures were the association of age with eliciting dose and the potential number of false negative outcomes.Results: A total of 1327 OFCs were performed in 707 patients. Of these, 514 (38.7%) were positive, 589 (44.4%) negative, and 224 (16.9%) inconclusive. In OFCs with inconclusive outcome, age appeared to be a significant predictor of the stop dose only for almond (p = .005). Objective symptoms occurred after the last dose step in 2%–13% of all OFCs with positive outcome. In our cohort, potential false negative outcomes may have been drawn in 27.6% of uneventful OFCs.Conclusions: Two third of children under 6 years of age successfully consumed all the provided doses during OFCs with a negative outcome. The eliciting dose for objective symptoms was not associated with age, and in a substantial number of OFCs with positive outcome, symptoms occurred after eating the final dose. These findings suggest that in case of an uneventful OFC, the outcome should be drawn only after a cumulative dose of 4.4 g has been consumed to avoid the risk of a potential false negative outcome.
- Open Access
- 19 January 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (3) , 216-218
Safe selection of children with a suspected food allergy to introduce peanut or tree nuts at home
- 19 January 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (3) , 216-218
Open AccessSafe selection of children with a suspected food allergy to introduce peanut or tree nuts at home
- Open Access
- 29 May 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (8) , 883-886
Investigation of novel salivary biomarkers in paediatric food allergy
- 29 May 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (8) , 883-886
Open AccessInvestigation of novel salivary biomarkers in paediatric food allergy
- Open Access
- 16 November 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 201-204
Low health‐related quality of life is associated with declining home introduction of suspected food allergens
- 16 November 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 201-204
Open AccessLow health‐related quality of life is associated with declining home introduction of suspected food allergens